Work

Broad Expression of a Minor Histocompatibility Antigen Results in Impaired Antitumor Immunity That Cannot Be Overcome with Dendritic Cell Vaccination

Year: 2012

Type: article

Abstract: Although allogeneic transplant remains a potent immunotherapy for high-risk hematopoetic malignancies, relapse is the main cause of treatment failure. We, and others, have shown that alloreactivity associated with minor histocompatibility antigen (miHA) mismatch reduces quantitative responses to vaccines targeting tumor-specific antigens. The effect of miHA mismatch on the antitumor response when the tumor also expresses the miHA has not been well-studied, and could provide important insight into the biology of the graft-versus-tumor effect.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2011.12.325

Authors: J.C. Shand, C.M. Capitini, H. Qin, T.J. Fry

Institutions: Johns Hopkins University, National Cancer Institute, National Institutes of Health

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650